Fidelity Investments’s Trinity Biotech TRIB Stock Holding History

Fidelity Investments’s Portfolio TRIB Stock Details TRIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Hold	0	–	-$9	–	5565
2025 Q4	–	Hold	0	–	–	–	5377
2014 Q3	–	Sell	-2,693	Closed	-$9.3M	–	2824
2014 Q2	$9.3M	Sell	2,693 -9,822	-78%	-$34.9M	﹤0.01%	2082
2014 Q1	$45.5M	Sell	12,515 -5,135	-29%	-$20.2M	0.01%	1375
2013 Q4	$66.6M	Buy	17,650 +4,098	+30%	+$14.8M	0.01%	1170
2013 Q3	$44.2M	Sell	13,552 -686	-5%	-$2.01M	0.01%	1354
2013 Q2	$36M	Buy	+14,238	New	+$35.4M	0.01%	1401

Other funds holding TRIB

HAIM

Hunter Associates Investment Management Pittsburgh, Pennsylvania $868M AUM 32.25% 1-Year Est. Return

YAG

Yorkville Advisors Global Mountainside, New Jersey $86.2M AUM 41.28% 1-Year Est. Return

Williams & Novak Westlake Village, California $151M AUM 27.43% 1-Year Est. Return

Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return

MAWA

Moss Adams Wealth Advisors Seattle, Washington $1.6B AUM 28.24% 1-Year Est. Return

IWA

Inspirion Wealth Advisors Libertyville, Illinois $874M AUM 16.23% 1-Year Est. Return

Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return

BCM

Becker Capital Management Portland, Oregon $3.72B AUM 31.98% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Fidelity Investments's TRIB Position: Q1 2026 in Review

Fidelity Investments held its Trinity Biotech (TRIB) position steady in Q1 2026 at 0 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #5565.

Fidelity Investments first reported a position in TRIB in Q2 2013 and has held it in 5 quarters since. The position peaked at $66.6M in Q4 2013. 21 funds tracked by Wall St. Rank hold TRIB as of Q1 2026.

Fidelity Investments held 0 shares of Trinity Biotech worth $0 as of Q1 2026.
Fidelity Investments left its Trinity Biotech share count unchanged in Q1 2026.
Trinity Biotech made up ﹤0.01% of Fidelity Investments's portfolio in Q1 2026, its #5565 holding.
Fidelity Investments first reported a position in Trinity Biotech in Q2 2013 and has held it in 5 quarters since.
Fidelity Investments's Trinity Biotech position peaked at $66.6M in Q4 2013.
21 funds tracked by Wall St. Rank held Trinity Biotech as of Q1 2026.

Based on Fidelity Investments's 13F filing for Q1 2026, filed 15 May 2026.